Palisade Bio (PALI) Cash from Financing Activities (2010 - 2026)

Palisade Bio (PALI) has reported Cash from Financing Activities for 17 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 1314.34% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $137.8 million (up 1788.1% YoY), while the FY2025 annual figure was $134.4 million, up 1303.05% from the prior year.
• Cash from Financing Activities slipped to $3.1 million in Q1 2026 per PALI's latest filing, from $131.3 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $131.3 million in Q4 2025 and bottomed at -$258000.0 in Q1 2025.
• Historically, Cash from Financing Activities has averaged $10.2 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities jumped 5203.45% — and 2025, when it plunged 112.75%.
• Palisade Bio's Cash from Financing Activities stood at $1.7 million in 2022, then plunged by 107.82% to -$134000.0 in 2023, then surged by 3205.97% to $4.2 million in 2024, then jumped by 3055.48% to $131.3 million in 2025, then plunged by 97.61% to $3.1 million in 2026.
• Business Quant data shows PALI's Cash from Financing Activities at $3.1 million in Q1 2026, $131.3 million in Q4 2025, and $3.4 million in Q3 2025.